Target
IL-2v
1 abstract
Abstract
Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma.Org: Novatim Immune Therapeutics (Zhejiang), Shanghai, China, Gracell Biotechnologies, Ltd., Fudan University, Shanghai, China,